Research programme: progesterone receptor modulators - Repros Therapeutics

Drug Profile

Research programme: progesterone receptor modulators - Repros Therapeutics

Alternative Names: Research programme: SPRMs - Repros Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Repros Therapeutics
  • Class
  • Mechanism of Action Selective progesterone receptor antagonists; Selective progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Endometriosis; Uterine leiomyoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Endometriosis in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Uterine-leiomyoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top